Parathyroid hormone and parathyroid hormone type-1 receptor accelerate myocyte differentiation

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Kimura, Shigemi ^a   Yoshioka, Kowasi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD34 ANTIGEN; MYOD PROTEIN; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR 1; TETRACYCLINE; TRANSCRIPTION FACTOR PAX7;

ANIMAL; CELL DIFFERENTIATION; CELL LINE; DRUG EFFECTS; EMBRYONIC STEM CELL; HUMAN; METABOLISM; MOUSE; PHYSIOLOGY; PROMOTER REGION; SKELETAL MUSCLE; SKELETAL MUSCLE SATELLITE CELL; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; ANTIGENS, CD34; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL LINE; EMBRYONIC STEM CELLS; HUMANS; MICE; MICE, INBRED MDX; MUSCLE FIBERS, SKELETAL; MYOD PROTEIN; PARATHYROID HORMONE; PAX7 TRANSCRIPTION FACTOR; PROMOTER REGIONS, GENETIC; RECEPTOR, PARATHYROID HORMONE, TYPE 1; SATELLITE CELLS, SKELETAL MUSCLE; TETRACYCLINE;

EID: 84902338502     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05066     Document Type: Article

References (42)

1. Koenig, M. et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50, 509-517 (1987).
2. Nelson, S. F., Crosbie, R. H., Miceli, M. C. & Spencer, M. J. Emerging genetic therapies to treat Duchenne muscular dystrophy. Curr.Opin.Neurol. 22, 532-538 (2009).
3. Goemans, N. M. et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med. 364, 1513-1522 (2011).
4. Ozasa, S. et al. Efficient conversion of ES cells into myogenic lineage using the gene-inducible system. Biochem. Biophys. Res. Co. 357, 957-963 (2007). (Pubitemid 46693664)
5. Yoshida, N. et al. Cell heterogeneity upon myogenic differentiation: downregulation of MyoD and Myf-5 generates 'reserve cells'. J. Cell Sci. 111, 769-779 (1998). (Pubitemid 28163885)
6. Mauro, A. Satellite cell of skeletal muscle fibers. J. Biophys. Biochem. Cy. 9, 493-495 (1961).
7. Seale, P. et al. Pax7 is required for the specification of myogenic satellite cells. Cell 102, 777-786 (2000).
8. Rooney, J. E., Gurpur, P. B., Yablonka-Reuveni, Z. & Burkin, D. J. Laminin-111 restores regenerative capacity in a mouse model for alpha7 integrin congenital myopathy. Am. J. Pathol. 174, 256-264 (2009).
9. Beauchamp, J. R. et al. Expression of CD34 and Myf5 defines the majority of quiescent adult skeletal muscle satellite cells. J. Cell Biol. 151, 1221-1234 (2000).
10. Covault, J. & Sanes, J. R. Distribution of N-CAM in synaptic and extrasynaptic portions of developing and adult skeletal muscle. J. Cell Biol. 102, 716-730 (1986). (Pubitemid 16013130)
11. Ratajczak, M. Z. et al. Expression of functional CXCR4 by muscle satellite cells and secretion of SDF-1 by muscle-derived fibroblasts is associated with the presence of both muscle progenitors in bonemarrow and hematopoietic stem/progenitor cells in muscles. Stem Cells 21, 363-371 (2003). (Pubitemid 36623177)
12. Wozniak, A. C. et al. C-Met expression and mechanical activation of satellite cells on cultured muscle fibers. J. Histochem. Cytochem. 51, 1437-1445 (2003). (Pubitemid 37444532)
13. Moss, F. P. & Leblond, C. P. Satellite cells as the source of nuclei in muscles of growing rats. Anat. Rec. 170, 421-435 (1971).
14. Bischoff, R. Regeneration of single skeletal muscle fibers in vitro. Anat. Rec. 182, 215-235 (1975).
15. Campion, D. R. The muscle satellite cell: a review. Int. Rev. Cytol. 87, 225-251 (1984). (Pubitemid 14141054)
16. Mannstadt, M., Juppner, H. & Gardella, T. J. Receptors for PTH and PTHrP: their biological importance and functional properties. Am. J. Physiol. 277, F665-675 (1999).
17. Blair, H. C., Sun, L.&Kohanski, R. A. Balanced regulation of proliferation, growth, differentiation, and degradation in skeletal cells. Ann. N.Y. Acad. Sci. 1116, 165-73 (2007). (Pubitemid 350274326)
18. Huber, B. C. et al. Comparison of parathyroid hormone and G-CSF treatment after myocardial infarction on perfusion and stem cell homing. Am. J. Physiol. -Heart C. 298, H1466-1471 (2010).
19. Song, G. J., Fiaschi-Taesch, N. & Bisello, A. Endogenous parathyroid hormonerelated protein regulates the expression of PTH type 1 receptor and proliferation of vascular smooth muscle cells. Mol. Endocrinol. 23, 1681-1690 (2009).
20. Goodell, M. A. et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat. Med. 3, 1337-1345 (1997). (Pubitemid 28011033)
21. Mukai, A. & Hashimoto, N. Localized cyclic AMP-dependent protein kinase activity is required for myogenic cell fusion. Exp. Cell Res. 314, 387-397 (2008). (Pubitemid 350216102)
22. Tanabe, Y., Esaki, K. & Nomura, T. Skeletal muscle pathology in X chromosomelinked muscular dystrophy (mdx) mouse. Acta Neuropathol. 69, 91-95 (1986). (Pubitemid 16146255)
23. Shimizu, E., Selvamurugan, N., Westendorf, J. J. & Partridge, N. C. Parathyroid hormone regulates histone deacetylases in osteoblasts. Ann. N.Y. Acad. Sci. 1116, 349-353 (2007). (Pubitemid 350274330)
24. Jacome-Galarza, C. E., Lee, S. K., Lorenzo, J. A. & Aguila, H. L. Parathyroid hormone regulates the distribution and osteoclastogenic potential of hematopoietic progenitors in the bonemarrow. J. Bone Miner. Res. 26, 1207-1216 (2011).
25. Esbrit, P. & Alcaraz, M. J. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies. Biochem. Pharmacol. 85, 1417-1423 (2013).
26. Lupp, A. et al. Immunohistochemical identification of the PTH1R parathyroid hormone receptor in normal and neoplastic human tissues. Eur. J. Endocrinol. 162, 979-986 (2010).
27. Schluter, K. D.&Piper, H. M. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc. Res. 37, 34-41 (1998). (Pubitemid 28122613)
28. Philbrick, W. M. et al. Defining the roles of parathyroid hormone-related protein in normal physiology. Physiol. Rev. 76, 127-173 (1996). (Pubitemid 26048280)
29. Lanske, B. et al. PTH/PTHrP receptor in early development and Indian hedgehogregulated bone growth. Science 273, 663-666 (1996). (Pubitemid 26262123)
30. Rugh, R. The mouse. (Oxford University press, Oxford; 1994).
31. Wen, Y. et al. Constitutive Notch activation upregulates Pax7 and promotes the self-renewal of skeletal muscle satellite cells. Mol. Cell Biol. 32, 2300-2311 (2012).
32. Rufo, A. et al. Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans. J. Bone Miner. Res. 26, 1891-1903 (2011).
33. Gray, S. K. et al. Black bear parathyroid hormone has greater anabolic effects on trabecular bone in dystrophin-deficient mice than in wild type mice. Bone 51, 578-585 (2012).
34. Niwa, H., Miyazaki, J. & Smith, A. G. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat. Genet. 24, 372-376 (2000). (Pubitemid 30187435)
35. Guo, J. et al. Signal-selectivity of parathyroid hormone (PTH)/PTH-related peptide receptor-mediated regulation of differentiation in conditionally immortalized growth-plate chondrocytes. Endocrinology 142, 1260-1268 (2001). (Pubitemid 32202837)
36. Hashimoto, N. et al. Immortalization of human myogenic progenitor cell clone retaining multipotentiality. Biochem. Bioph. Res. Co. 348, 1383-1388 (2006). (Pubitemid 44291352)
37. Wada, M. R., Inagawa-Ogashiwa, M., Shimizu, S., Yasumoto, S. & Hashimoto, N. Generation of different fates from multipotent muscle stem cells. Development 129, 2987-2995 (2002). (Pubitemid 34874276)
38. Kuwahara, M. et al. Expression of bone type 1 PTH receptor in rats with chronic renal failure. Clin. Exp. Nephrol. 11, 34-40 (2007). (Pubitemid 46474967)
39. Grefte, S., Kuijpers, M. A., Kuijpers-Jagtman, A. M., Torensma, R. & Von den Hoff, J. W. Myogenic capacity of muscle progenitor cells from head and limb muscles. Eur. J. Oral. Sci. 120, 38-45 (2012).
40. Kimura, S. et al. Novel mutation in splicing donor of dystrophin gene first exon in a patient with dilated cardiomyopathy but no clinical signs of skeletal myopathy. J. Child Neurol. 22, 901-906 (2007). (Pubitemid 47261248)
41. Van Putten, M. et al. A 3 months mild functional test regime does not affect disease parameters in young mdx mice. Neuromuscular Disord. 20, 273-280 (2010).
42. Aoki, Y. et al. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc. Natl. Acad. Sci. U.S.A. 109,13763-13768 (2012). Technology